The Rationale Behind CheckMate-275 in Metastatic Bladder Cancer

Video

Matthew Galsky, MD, professor of Medicine, Mount Sinai School of Medicine, discusses the significant findings in, and the rationale behind conducting the CheckMate-275 trial during an interview at the 2016 ESMO Congress.

Related Videos
Related Content